| Project/Area Number |
05671477
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Tokyo Medical College |
|---|
Principal Investigator |
MURAMATSU Ryuji Tokyo Medical College, Ophthalmology, Associate Professor, 医学部, 助教授 (90074757)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHIMIZU Nobuaki Tokyo Medical College, Ophthalmology, Instructor, 医学部, 助手 (20246242)
SONE Ryuichiro Tokyo Medical College, Ophthalmology, Instructor, 医学部, 助手 (90206681)
大塚 裕子 東京医科大学, 医学部, 助手 (00233180)
|
|---|
| Project Period (FY) |
1993 – 1994
|
| Project Status |
Completed (Fiscal Year 1994)
|
| Budget Amount *help |
¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 1994: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1993: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Keywords | Transplantation / ICAM-1 / LFA-1 / Cyclosporin A / Rat / Keratoplasty / Rejection / 細胞接着因子 |
|---|
| Research Abstract |
Fisher 344 rat donor grafts were transplanted to Lewis rat recipients using 3 mm diamter trephination, and the grafts were assessed postoperatively by slit lamp examination. All 8 grafts in a non-treatment group rejected at a mean of 10.5 + 2.5 days. In contrast, intramuscular injection of 5 mg/kg cyclosporin A daily for 14 days resulted in suppression of rejection in 5 of 5 grafts that were followed up to 30 days postoperatively, although a lesser dose of 2 mg/kg resulted in rejection at 9 to 14 days in 4 of 4 grafts. Cyclosporin A (2mg/kg), combined with either anti-ICAM-1 monoclonal antibody (1mg/kg) or anti-LFA-1 monoclonal antibody (1mg/kg), also failed to suppress rejection. However, when cyclosporin A (2mg/kg) was administered with both anti-ICAM-1 and anti-LFA-1 monoclonal antibodies in 5 rats, graft rejection was observed in only 1 rat at 18 days, while the grafts in the other 4 rats remained clear up to 30 days. In conclusion, combination therapy using cyclosporin A,and both anti-ICAM-1 and anti-LFA-1 monoclonal antibodies, appears capable of suppressing rejection in this animal corneal transplant model.
|
